BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Harrison SA, Neff G, Guy CD, Bashir MR, Paredes AH, Frias JP, Younes Z, Trotter JF, Gunn NT, Moussa SE, Kohli A, Nelson K, Gottwald M, Chang WCG, Yan AZ, DePaoli AM, Ling L, Lieu HD. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. Gastroenterology 2021;160:219-231.e1. [PMID: 32781086 DOI: 10.1053/j.gastro.2020.08.004] [Cited by in Crossref: 103] [Cited by in F6Publishing: 102] [Article Influence: 51.5] [Reference Citation Analysis]
Number Citing Articles
1 Loomba R, Lawitz EJ, Frias JP, Ortiz-Lasanta G, Johansson L, Franey BB, Morrow L, Rosenstock M, Hartsfield CL, Chen CY, Tseng L, Charlton RW, Mansbach H, Margalit M. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. Lancet Gastroenterol Hepatol 2023;8:120-32. [PMID: 36521501 DOI: 10.1016/S2468-1253(22)00347-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Verbiest A, Jeppesen PB, Joly F, Vanuytsel T. The Role of a Colon-in-Continuity in Short Bowel Syndrome. Nutrients 2023;15:628. [DOI: 10.3390/nu15030628] [Reference Citation Analysis]
3 Jin L, Yang R, Geng L, Xu A. Fibroblast Growth Factor-Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications. Annu Rev Pharmacol Toxicol 2023;63:359-82. [PMID: 36100222 DOI: 10.1146/annurev-pharmtox-032322-093904] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Rong L, Zou J, Ran W, Qi X, Chen Y, Cui H, Guo J. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne) 2022;13:1087260. [PMID: 36726464 DOI: 10.3389/fendo.2022.1087260] [Reference Citation Analysis]
5 Gillard J, Leclercq IA. Biological tuners to reshape the bile acid pool for therapeutic purposes in non-alcoholic fatty liver disease. Clin Sci (Lond) 2023;137:65-85. [PMID: 36601783 DOI: 10.1042/CS20220697] [Reference Citation Analysis]
6 Lawitz EJ, Bhandari BR, Ruane PJ, Kohli A, Harting E, Ding D, Chuang JC, Huss RS, Chung C, Myers RP, Loomba R. Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. Clin Gastroenterol Hepatol 2023;21:143-152.e3. [PMID: 34999207 DOI: 10.1016/j.cgh.2021.12.044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Li Y, Lei R, Lei H, Xiong Q, Xie F, Yao C, Feng P. Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Eur J Gastroenterol Hepatol 2023;35:1-14. [PMID: 36468565 DOI: 10.1097/MEG.0000000000002471] [Reference Citation Analysis]
8 Lee KC, Wu PS, Lin HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clin Mol Hepatol 2023;29:77-98. [PMID: 36226471 DOI: 10.3350/cmh.2022.0237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Rasmussen DGK, Anstee QM, Torstenson R, Golding B, Patterson SD, Brass C, Thakker P, Harrison S, Billin AN, Schuppan D, Dufour JF, Andersson A, Wigley I, Shumbayawonda E, Dennis A, Schoelch C, Ratziu V, Yunis C, Bossuyt P, Karsdal MA. NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned. J Hepatol 2022:S0168-8278(22)03325-6. [PMID: 36526000 DOI: 10.1016/j.jhep.2022.11.028] [Reference Citation Analysis]
10 Coassolo L, Dannieskiold-Samsøe NB, Zhao M, Allen H, Svensson KJ. New players of the adipose secretome: Therapeutic opportunities and challenges. Curr Opin Pharmacol 2022;67:102302. [PMID: 36195010 DOI: 10.1016/j.coph.2022.102302] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Tay PWL, Ng CH, Lin SY, Chin YH, Xiao J, Lim WH, Lim SY, Fu CE, Chan KE, Quek J, Tan DJH, Chew N, Syn N, Keitoku T, Tamaki N, Siddiqui MS, Noureddin M, Muthiah M, Huang DQ, Loomba R. Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants. Am J Gastroenterol 2022. [PMID: 36191268 DOI: 10.14309/ajg.0000000000002042] [Reference Citation Analysis]
12 Lei Y, Tang L, Chen Q, Wu L, He W, Tu D, Wang S, Chen Y, Liu S, Xie Z, Wei H, Yang S, Tang B. Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism. Nat Commun 2022;13:6862. [PMID: 36369291 DOI: 10.1038/s41467-022-34671-1] [Reference Citation Analysis]
13 Ratziu V, Harrison SA, Loustaud-Ratti V, Bureau C, Lawitz E, Abdelmalek M, Alkhouri N, Francque S, Girma H, Darteil R, Couchoux H, Wolf M, Sanyal A, Vonderscher J, Scalfaro P. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. J Hepatol 2022:S0168-8278(22)03160-9. [PMID: 36334688 DOI: 10.1016/j.jhep.2022.10.023] [Reference Citation Analysis]
14 Tilg H, Adolph TE, Trauner M. Gut-liver axis: Pathophysiological concepts and clinical implications. Cell Metab 2022;34:1700-18. [PMID: 36208625 DOI: 10.1016/j.cmet.2022.09.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Prida E, Álvarez-delgado S, Pérez-lois R, Soto-tielas M, Estany-gestal A, Fernø J, Seoane LM, Quiñones M, Al-massadi O. Liver Brain Interactions: Focus on FGF21 a Systematic Review. IJMS 2022;23:13318. [DOI: 10.3390/ijms232113318] [Reference Citation Analysis]
16 Matye DJ, Qin X, Hasan MN, Gu L, Clayton Y, Li F, Li T. Effects of apical sodium-bile acid transporter inhibitor and obeticholic acid co-treatment in experimental non-alcoholic steatohepatitis. Liver Research 2022. [DOI: 10.1016/j.livres.2022.11.002] [Reference Citation Analysis]
17 Koda Y, Nakamoto N, Kanai T. Regulation of Progression and Resolution of Liver Fibrosis by Immune Cells. Semin Liver Dis 2022;42:475-88. [PMID: 36208620 DOI: 10.1055/a-1957-6384] [Reference Citation Analysis]
18 Brennan PN, Dillon JF, McCrimmon R. Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis. touchREV Endocrinol 2022;18:148-55. [PMID: 36694893 DOI: 10.17925/EE.2022.18.2.148] [Reference Citation Analysis]
19 Li L, Sun H, Chen J, Ding C, Yang X, Han H, Sun Q. Treatment of non-alcoholic steatohepatitis with recombinant Orosomucoid 2, an acute phase protein that attenuates the Erk1/2-PPARγ-Cd36 signaling pathway.. [DOI: 10.1101/2022.10.22.513320] [Reference Citation Analysis]
20 Zhang D, Zhang Y, Sun B. The Molecular Mechanisms of Liver Fibrosis and Its Potential Therapy in Application. IJMS 2022;23:12572. [DOI: 10.3390/ijms232012572] [Reference Citation Analysis]
21 Chen L, Lv X, Kan M, Wang R, Wang H, Zang H. Critical Overview of Hepatic Factors That Link Non-Alcoholic Fatty Liver Disease and Acute Kidney Injury: Physiology and Therapeutic Implications. IJMS 2022;23:12464. [DOI: 10.3390/ijms232012464] [Reference Citation Analysis]
22 Ortiz-lópez N, Fuenzalida C, Dufeu MS, Pinto-león A, Escobar A, Poniachik J, Roblero JP, Valenzuela-pérez L, Beltrán CJ. The immune response as a therapeutic target in non-alcoholic fatty liver disease. Front Immunol 2022;13:954869. [DOI: 10.3389/fimmu.2022.954869] [Reference Citation Analysis]
23 Dufour JF, Anstee QM, Bugianesi E, Harrison S, Loomba R, Paradis V, Tilg H, Wong VW, Zelber-Sagi S. Current therapies and new developments in NASH. Gut 2022;71:2123-34. [PMID: 35710299 DOI: 10.1136/gutjnl-2021-326874] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
24 Song L, Wang L, Hou Y, Zhou J, Chen C, Ye X, Dong W, Gao H, Liu Y, Qiao G, Pan T, Chen Q, Cao Y, Hu F, Rao Z, Chen Y, Han Y, Zheng M, Luo Y, Li X, Chen Y, Huang Z. FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis. Hepatology 2022;76:1105-20. [PMID: 35152446 DOI: 10.1002/hep.32404] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
25 Chrysavgis L, Giannakodimos I, Chatzigeorgiou A, Tziomalos K, Papatheodoridis G, Cholongitas E. The role of fibroblast growth factor 19 in the pathogenesis of nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2022;:1-15. [PMID: 36124827 DOI: 10.1080/17474124.2022.2127408] [Reference Citation Analysis]
26 Suri J, Borja S, Lim JK. Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis. World J Gastroenterol 2022; 28(35): 5129-5140 [DOI: 10.3748/wjg.v28.i35.5129] [Reference Citation Analysis]
27 Cai J, Rimal B, Jiang C, Chiang JY, Patterson AD. Bile acid metabolism and signaling, the microbiota, and metabolic disease. Pharmacology & Therapeutics 2022;237:108238. [DOI: 10.1016/j.pharmthera.2022.108238] [Reference Citation Analysis]
28 Harrison SA, Ruane PJ, Freilich B, Neff G, Patil R, Behling C, Hu C, Shringarpure R, de Temple B, Fong E, Tillman EJ, Rolph T, Cheng A, Yale K. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Rep 2023;5:100563. [PMID: 36644237 DOI: 10.1016/j.jhepr.2022.100563] [Reference Citation Analysis]
29 Liu Y, Liu T, Zhao X, Gao Y. New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease. Cell Mol Life Sci 2022;79:486. [PMID: 35978227 DOI: 10.1007/s00018-022-04509-6] [Reference Citation Analysis]
30 Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther 2022;7:287. [PMID: 35963848 DOI: 10.1038/s41392-022-01119-3] [Reference Citation Analysis]
31 Wang Z, Ye M, Zhang XJ, Zhang P, Cai J, Li H, She ZG. Impact of NAFLD and its pharmacotherapy on lipid profile and CVD. Atherosclerosis 2022;355:30-44. [PMID: 35872444 DOI: 10.1016/j.atherosclerosis.2022.07.010] [Reference Citation Analysis]
32 Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease. J Intern Med 2022. [PMID: 35796150 DOI: 10.1111/joim.13531] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Liu T, Tang X, Cui Y, Xiong X, Xu Y, Hu S, Feng S, Shao L, Ren Y, Miao H, Zhang H, Zhu X, Zhang Y, Wang C, Kosuru R. Fibroblast Growth Factor 19 Improves LPS-Induced Lipid Disorder and Organ Injury by Regulating Metabolomic Characteristics in Mice. Oxidative Medicine and Cellular Longevity 2022;2022:1-19. [DOI: 10.1155/2022/9673512] [Reference Citation Analysis]
34 Tsochatzis EA. Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design. The Lancet Gastroenterology & Hepatology 2022;7:586-7. [DOI: 10.1016/s2468-1253(22)00049-8] [Reference Citation Analysis]
35 Fuchs CD, Trauner M. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nat Rev Gastroenterol Hepatol 2022;19:432-50. [PMID: 35165436 DOI: 10.1038/s41575-021-00566-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 19.0] [Reference Citation Analysis]
36 Harrison SA, Abdelmalek MF, Neff G, Gunn N, Guy CD, Alkhouri N, Bashir MR, Freilich B, Kohli A, Khazanchi A, Sheikh MY, Leibowitz M, Rinella ME, Siddiqui MS, Kipnes M, Moussa SE, Younes ZH, Bansal M, Baum SJ, Borg B, Ruane PJ, Thuluvath PJ, Gottwald M, Khan M, Chen C, Melchor-khan L, Chang W, Depaoli AM, Ling L, Lieu HD. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. The Lancet Gastroenterology & Hepatology 2022;7:603-16. [DOI: 10.1016/s2468-1253(22)00017-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
37 Ng CH, Xiao J, Lim WH, Chin YH, Yong JN, Tan DJH, Tay P, Syn N, Foo R, Chan M, Chew N, Tan EX, Huang DQ, Dan YY, Tamaki N, Siddiqui MS, Sanyal AJ, Loomba R, Noureddin M, Muthiah MD. Placebo effect on progression and regression in NASH: Evidence from a meta-analysis. Hepatology 2022;75:1647-61. [PMID: 34990037 DOI: 10.1002/hep.32315] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
38 Katafuchi T, Makishima M. Molecular Basis of Bile Acid-FXR-FGF15/19 Signaling Axis. IJMS 2022;23:6046. [DOI: 10.3390/ijms23116046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
39 Branković M, Jovanović I, Dukić M, Radonjić T, Oprić S, Klašnja S, Zdravković M. Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis. Int J Mol Sci 2022;23:5146. [PMID: 35563534 DOI: 10.3390/ijms23095146] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
40 Chew NWS, Ng CH, Muthiah MD, Sanyal AJ. Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. Curr Atheroscler Rep 2022. [PMID: 35507280 DOI: 10.1007/s11883-022-01027-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
41 Panzitt K, Zollner G, Marschall H, Wagner M. Recent advances on FXR-targeting therapeutics. Molecular and Cellular Endocrinology 2022. [DOI: 10.1016/j.mce.2022.111678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Marjot T, Ray DW, Tomlinson JW. Is it time for chronopharmacology in NASH? J Hepatol 2022;76:1215-24. [PMID: 35066087 DOI: 10.1016/j.jhep.2021.12.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
43 Ng CH, Muthiah MD, Xiao J, Chin YH, Lim G, Lim WH, Tay P, Tan DJH, Yong JN, Pan XH, Koh JWH, Chew N, Syn N, Tan E, Huang DQ, Siddiqui MS, Loomba R, Sanyal AJ, Noureddin M. Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis. Aliment Pharmacol Ther 2022;55:1076-87. [PMID: 35285529 DOI: 10.1111/apt.16808] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
44 Shi YW, Fan JG. Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis. Acta Pharmacol Sin 2022;43:1191-9. [PMID: 34907360 DOI: 10.1038/s41401-021-00822-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
45 Yang YY, Xie L, Zhang NP, Zhou D, Liu TT, Wu J. Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis. Acta Pharmacol Sin 2022;43:1180-90. [PMID: 35190696 DOI: 10.1038/s41401-022-00860-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
46 Jiao TY, Ma YD, Guo XZ, Ye YF, Xie C. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease. Acta Pharmacol Sin 2022;43:1103-19. [PMID: 35217817 DOI: 10.1038/s41401-022-00880-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
47 Tang S, Mao X, Chen Y, Yan L, Ye L, Li S. Reactive Oxygen Species Induce Fatty Liver and Ischemia-Reperfusion Injury by Promoting Inflammation and Cell Death. Front Immunol 2022;13:870239. [DOI: 10.3389/fimmu.2022.870239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
48 Umemura A, Kataoka S, Okuda K, Seko Y, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. Potential Therapeutic Targets and Promising Agents for Combating NAFLD. Biomedicines 2022;10:901. [DOI: 10.3390/biomedicines10040901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Kemas AM, Youhanna S, Lauschke VM. Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development. Expert Review of Precision Medicine and Drug Development 2022;7:39-49. [DOI: 10.1080/23808993.2022.2053285] [Reference Citation Analysis]
50 Ampuero J, Gallego-Durán R, Maya-Miles D, Montero R, Gato S, Rojas Á, Gil A, Muñoz R, Romero-Gómez M. Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD. J Gastroenterol 2022. [PMID: 35325295 DOI: 10.1007/s00535-022-01860-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Guthrie G, Vonderohe C, Burrin D. Fibroblast growth factor 15/19 expression, regulation, and function: An overview. Mol Cell Endocrinol 2022;:111617. [PMID: 35301051 DOI: 10.1016/j.mce.2022.111617] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
52 Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol 2022;76:506-17. [PMID: 34740705 DOI: 10.1016/j.jhep.2021.10.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
53 Puengel T, Liu H, Guillot A, Heymann F, Tacke F, Peiseler M. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:2668. [PMID: 35269812 DOI: 10.3390/ijms23052668] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
54 Guo JY, Chen HH, Lee WJ, Chen SC, Lee SD, Chen CY. Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Gastric Bypass. Nutrients 2022;14:645. [PMID: 35277004 DOI: 10.3390/nu14030645] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
55 Sebastiani G, Patel K, Ratziu V, Feld JJ, Neuschwander-tetri BA, Pinzani M, Petta S, Berzigotti A, Metrakos P, Shoukry N, Brunt EM, Tang A, Cobbold JF, Ekoe J, Seto K, Ghali P, Chevalier S, Anstee QM, Watson H, Bajaj H, Stone J, Swain MG, Ramji A. Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). CanLivJ 2022;5:61-90. [DOI: 10.3138/canlivj-2021-0030] [Reference Citation Analysis]
56 Garbuzenko DV. Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2022;31:16-24. [DOI: 10.22416/1382-4376-2021-31-5-16-24] [Reference Citation Analysis]
57 白 玉. Expression Regulation and Bioactivity of Fibroblast Growth Factor 19/15. PI 2022;11:161-167. [DOI: 10.12677/pi.2022.113020] [Reference Citation Analysis]
58 Tapper EB, Fleming C, Rendon A, Fernandes J, Johansen P, Augusto M, Nair S. The Burden of Nonalcoholic Steatohepatitis: A Systematic Review of Epidemiology Studies. Gastro Hep Advances 2022;1:1049-1087. [DOI: 10.1016/j.gastha.2022.06.016] [Reference Citation Analysis]
59 Bajaj JS, Khoruts A. Microbial Therapeutics in Liver Disease. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00193-6] [Reference Citation Analysis]
60 Kovalic AJ. Pharmacotherapeutic Impact on Nonalcoholic Steatohepatitis Histology: A Systematic Review and Network Meta-analysis. J Clin Exp Hepatol 2022;12:1057-68. [PMID: 35814516 DOI: 10.1016/j.jceh.2022.01.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 2022;71:194-209. [PMID: 34615727 DOI: 10.1136/gutjnl-2021-324305] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 28.0] [Reference Citation Analysis]
62 Farooqui N, Elhence A, Shalimar. A Current Understanding of Bile Acids in Chronic Liver Disease. J Clin Exp Hepatol 2022;12:155-73. [PMID: 35068796 DOI: 10.1016/j.jceh.2021.08.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
63 Lee YA, Friedman SL. Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies. J Intern Med 2022;291:11-31. [PMID: 34564899 DOI: 10.1111/joim.13380] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
64 Wang Y, Zheng L, Zhou Z, Yao D, Huang Y, Liu B, Duan Y, Li Y. Review article: insights into the bile acid-gut microbiota axis in intestinal failure-associated liver disease-redefining the treatment approach. Aliment Pharmacol Ther 2022;55:49-63. [PMID: 34713470 DOI: 10.1111/apt.16676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021;3:1596-607. [DOI: 10.1038/s42255-021-00501-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
66 Yang M, Khoukaz L, Qi X, Kimchi ET, Staveley-O'Carroll KF, Li G. Diet and Gut Microbiota Interaction-Derived Metabolites and Intrahepatic Immune Response in NAFLD Development and Treatment. Biomedicines 2021;9:1893. [PMID: 34944709 DOI: 10.3390/biomedicines9121893] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
67 Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, Glisic T, Filipovic N, Al Kiswani J, Djokovic A, Kapor S, Kapor S, Bukumiric Z, Starcevic A. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:13219. [PMID: 34948020 DOI: 10.3390/ijms222413219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
68 Gadaleta RM, Moschetta A. Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver. J Hepatol 2021;75:1440-51. [PMID: 34364916 DOI: 10.1016/j.jhep.2021.07.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
69 Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. World J Hepatol 2021; 13(11): 1584-1610 [PMID: 34904031 DOI: 10.4254/wjh.v13.i11.1584] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
70 Cheung A, Ahmed A. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks. Clin Exp Gastroenterol 2021;14:457-65. [PMID: 34819740 DOI: 10.2147/CEG.S226130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
71 He LH, Yao DH, Wang LY, Zhang L, Bai XL. Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. Front Microbiol 2021;12:761836. [PMID: 34795655 DOI: 10.3389/fmicb.2021.761836] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
72 Qu W, Ma T, Cai J, Zhang X, Zhang P, She Z, Wan F, Li H. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne) 2021;8:761538. [PMID: 34746195 DOI: 10.3389/fmed.2021.761538] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
73 Roberts SK, Majeed A. A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Ther Targets 2021;25:889-95. [PMID: 34727818 DOI: 10.1080/14728222.2021.1999416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
74 Radun R, Trauner M. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. Semin Liver Dis 2021;41:461-75. [PMID: 34289507 DOI: 10.1055/s-0041-1731707] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
75 Pereira SDC, Benoit B, de Aguiar Junior FCA, Chanon S, Vieille-Marchiset A, Pesenti S, Ruzzin J, Vidal H, Toscano AE. Fibroblast growth factor 19 as a countermeasure to muscle and locomotion dysfunctions in experimental cerebral palsy. J Cachexia Sarcopenia Muscle 2021. [PMID: 34704398 DOI: 10.1002/jcsm.12819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Muthiah MD, Ng CH, Xiao J, Chin YH, Lim G, Lim WH, Tay P, Hao Tan DJ, Yong JN, Pan X, Heng Koh JW, Chew N, Syn N, Tan E, Huang DQ, Siddiqui MS, Loomba R, Sanyal AJ, Noureddin M. Analysis of Mechanistic Pathways in the Treatment of Non-Alcoholic Steatohepatitis. Evidence from a Bayesian Network Meta-Analysis.. [DOI: 10.1101/2021.10.22.21265361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Niu L, Sulek K, Vasilopoulou CG, Santos A, Wewer Albrechtsen NJ, Rasmussen S, Meier F, Mann M. Defining NASH from a Multi-Omics Systems Biology Perspective. J Clin Med 2021;10:4673. [PMID: 34682795 DOI: 10.3390/jcm10204673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, Arrese M, Fracanzani AL, Ben Bashat D, Lackner K, Gorfine T, Kadosh S, Oren R, Halperin M, Hayardeny L, Loomba R, Friedman S, Sanyal AJ; ARREST investigator study group. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med 2021;27:1825-35. [PMID: 34621052 DOI: 10.1038/s41591-021-01495-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
79 Shao W, Jin T. Hepatic hormone FGF21 and its analogues in clinical trials. Chronic Diseases and Translational Medicine 2021. [DOI: 10.1016/j.cdtm.2021.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
80 Majzoub AM, Nayfeh T, Barnard A, Munaganuru N, Dave S, Singh S, Murad MH, Loomba R. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther 2021;54:880-9. [PMID: 34435378 DOI: 10.1111/apt.16583] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 12.5] [Reference Citation Analysis]
81 Febbraio MA, Karin M. "Sweet death": Fructose as a metabolic toxin that targets the gut-liver axis. Cell Metab 2021:S1550-4131(21)00423-X. [PMID: 34619076 DOI: 10.1016/j.cmet.2021.09.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
82 Cohen CC, Castillo-Leon E, Farris AB, Caltharp SA, Cleeton RL, Sinclair EM, Shevell DE, Karsdal MA, Nielsen MJF, Leeming DJ, Vos MB. PRO-C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD. Hepatol Commun 2021;5:1860-72. [PMID: 34558828 DOI: 10.1002/hep4.1766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Phan P, Saikia BB, Sonnaila S, Agrawal S, Alraawi Z, Kumar TKS, Iyer S. The Saga of Endocrine FGFs. Cells 2021;10:2418. [PMID: 34572066 DOI: 10.3390/cells10092418] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
84 Van Gaal LF, Mertens J, Francque S, De Block C. Therapeutic approaches for non-alcoholic steatohepatitis. Ther Adv Endocrinol Metab 2021;12:20420188211034300. [PMID: 34497708 DOI: 10.1177/20420188211034300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
85 Kalo E, Read S, Ahlenstiel G. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. Livers 2021;1:147-79. [DOI: 10.3390/livers1030014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
86 Erhardtsen E, Rasmussen DGK, Frederiksen P, Leeming DJ, Shevell D, Gluud LL, Karsdal MA, Aithal GP, Schattenberg JM. Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosis. JHEP Rep 2021;3:100317. [PMID: 34466796 DOI: 10.1016/j.jhepr.2021.100317] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
87 Pan Z, Fan JG, Eslam M. An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities. Curr Opin Pharmacol 2021;60:170-6. [PMID: 34455284 DOI: 10.1016/j.coph.2021.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
88 Karsdal MA, Genovese F, Rasmussen DGK, Bay-Jensen AC, Mortensen JH, Holm Nielsen S, Willumsen N, Jensen C, Manon-Jensen T, Jennings L, Reese-Petersen AL, Henriksen K, Sand JM, Bager C, Leeming DJ. Considerations for understanding protein measurements: Identification of formation, degradation and more pathological relevant epitopes. Clin Biochem 2021;97:11-24. [PMID: 34453894 DOI: 10.1016/j.clinbiochem.2021.08.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Brown E, Hydes T, Hamid A, Cuthbertson DJ. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Clin Ther 2021;43:1476-504. [PMID: 34446271 DOI: 10.1016/j.clinthera.2021.07.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
90 Nawrot M, Peschard S, Lestavel S, Staels B. Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. Metabolism 2021;123:154844. [PMID: 34343577 DOI: 10.1016/j.metabol.2021.154844] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
91 Smati S, Canivet CM, Boursier J, Cariou B. Anti-diabetic drugs and NASH: from current options to promising perspectives. Expert Opin Investig Drugs 2021;30:813-25. [PMID: 34214406 DOI: 10.1080/13543784.2021.1951701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
92 Caballeria-Casals A, Micó-Carnero M, Rojano-Alfonso C, Maroto-Serrat C, Casillas-Ramírez A, Álvarez-Mercado AI, Gracia-Sancho J, Peralta C. Role of FGF15 in Hepatic Surgery in the Presence of Tumorigenesis: Dr. Jekyll or Mr. Hyde? Cells 2021;10:1421. [PMID: 34200439 DOI: 10.3390/cells10061421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2021;18:373-92. [PMID: 33568794 DOI: 10.1038/s41575-020-00408-y] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 51.5] [Reference Citation Analysis]
94 Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-24. [PMID: 33894145 DOI: 10.1016/S0140-6736(20)32511-3] [Cited by in Crossref: 208] [Cited by in F6Publishing: 264] [Article Influence: 104.0] [Reference Citation Analysis]
95 Gastaldelli A, Stefan N, Häring HU. Liver-targeting drugs and their effect on blood glucose and hepatic lipids. Diabetologia 2021;64:1461-79. [PMID: 33877366 DOI: 10.1007/s00125-021-05442-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
96 Bianco C, Casirati E, Malvestiti F, Valenti L. Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. JHEP Rep 2021;3:100284. [PMID: 34027340 DOI: 10.1016/j.jhepr.2021.100284] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
97 Huisman TM, Dieterich DT, Friedman SL. Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update. J Exp Pharmacol 2021;13:329-38. [PMID: 33776490 DOI: 10.2147/JEP.S265286] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
98 Kulkarni AV, Tevethia HV, Arab JP, Candia R, Premkumar M, Kumar P, Sharma M, Reddy DN, Padaki NR. Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2021;45:101675. [PMID: 33722778 DOI: 10.1016/j.clinre.2021.101675] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
99 Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease.BMJ. 2021;372:m4747. [PMID: 33461969 DOI: 10.1136/bmj.m4747] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 21.0] [Reference Citation Analysis]
100 Acharya C, Bajaj JS. Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. Gastroenterology 2021;160:556-72. [PMID: 33253686 DOI: 10.1053/j.gastro.2020.10.056] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 13.5] [Reference Citation Analysis]
101 Abdelmalek MF. Nonalcoholic fatty liver disease: another leap forward. Nat Rev Gastroenterol Hepatol 2021;18:85-6. [PMID: 33420415 DOI: 10.1038/s41575-020-00406-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 17.0] [Reference Citation Analysis]
102 Talukdar S, Kharitonenkov A. FGF19 and FGF21: In NASH we trust. Mol Metab 2021;46:101152. [PMID: 33383173 DOI: 10.1016/j.molmet.2020.101152] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
103 Finan B, Parlee SD, Yang B. Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH. Mol Metab 2021;46:101153. [PMID: 33359400 DOI: 10.1016/j.molmet.2020.101153] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
104 Henriksson E, Andersen B. FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human. Front Endocrinol (Lausanne) 2020;11:601349. [PMID: 33414764 DOI: 10.3389/fendo.2020.601349] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
105 Tillman EJ, Rolph T. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Front Endocrinol (Lausanne) 2020;11:601290. [PMID: 33381084 DOI: 10.3389/fendo.2020.601290] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 15.7] [Reference Citation Analysis]